• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[多发性硬化症:诊断程序与当前治疗进展]

[Multiple sclerosis: diagnostic procedures and current therapeutic developments].

作者信息

Kappos L

机构信息

Neurologische Universitätsklinik, Kantonsspital Basel.

出版信息

Schweiz Med Wochenschr. 1995 Jun 24;125(25):1251-63.

PMID:7610362
Abstract

The diagnosis of multiple sclerosis remains a clinical one. It is based on the documentation of lesions at two or more sites of the CNS and of two or more relapses in relapsing-remitting disease, or persistent deterioration for 6 months in primarily chronic-progressive disease. Because no symptom and no result of a paraclinical investigation is specific enough, a careful differential diagnostic work up by a physician competent in clinical neurology is essential. CSF examination, blood serology, MRI and in some cases evoked potentials may help in this work-up. The results of recently completed controlled trials suggest that, besides high dose steroid treatment of acute relapses, immunomodulatory treatments may help to improve the prognosis in relapsing-remitting phase of the disease. Treatments that will enter clinical practice in the next year or two are recombinant interferon beta-1b and -1a and perhaps copolymer 1. Non-selective immunosuppressants (azathioprine, in more severe cases other substances with more intensive cytostatic activity) also have a place in selected cases. The efficacy of such treatment in secondary chronic-progressive disease as well as the indication for very early treatment are now under investigation. Some possible future developments in diagnosis and therapy of MS are discussed.

摘要

多发性硬化症的诊断仍然依靠临床判断。其依据是中枢神经系统两个或更多部位出现病变的记录,以及复发缓解型疾病出现两次或更多次复发,或原发慢性进展型疾病持续恶化6个月。由于没有任何症状和辅助临床检查结果具有足够的特异性,因此由临床神经学方面的专业医生进行细致的鉴别诊断工作至关重要。脑脊液检查、血液血清学检查、磁共振成像以及在某些情况下的诱发电位检查可能有助于此项鉴别诊断工作。最近完成的对照试验结果表明,除了对急性复发进行大剂量类固醇治疗外,免疫调节治疗可能有助于改善疾病复发缓解期的预后。未来一两年内将进入临床应用的治疗方法是重组干扰素β-1b和-1a,或许还有共聚肽1。非选择性免疫抑制剂(硫唑嘌呤,在病情更严重的情况下使用其他具有更强细胞毒性活性的物质)在特定病例中也有应用。目前正在研究此类治疗在继发慢性进展型疾病中的疗效以及极早期治疗的指征。文中还讨论了多发性硬化症诊断和治疗未来可能的一些发展情况。

相似文献

1
[Multiple sclerosis: diagnostic procedures and current therapeutic developments].[多发性硬化症:诊断程序与当前治疗进展]
Schweiz Med Wochenschr. 1995 Jun 24;125(25):1251-63.
2
[Immunomodulatory therapy in multiple sclerosis].[多发性硬化症的免疫调节治疗]
Ideggyogy Sz. 2004 Nov 20;57(11-12):401-16.
3
[Therapy of multiple sclerosis].[多发性硬化症的治疗]
Neuropsychopharmacol Hung. 2009 Mar;11(1):23-6.
4
Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.类固醇和免疫抑制的作用以及干扰素β-1b在多发性硬化症中的效果。
West J Med. 1994 Sep;161(3):292-8.
5
Early treatment trials with interferon beta in multiple sclerosis.多发性硬化症中干扰素β的早期治疗试验。
Mult Scler. 1995;1 Suppl 1:S17-21.
6
Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.重组人干扰素β治疗复发缓解型和继发进展型多发性硬化症。
Mult Scler. 1995;1 Suppl 1:S48-50.
7
[Is immunosuppression a future therapeutic strategy for multiple sclerosis?].[免疫抑制会成为多发性硬化症未来的治疗策略吗?]
Pathol Biol (Paris). 2000 Mar;48(2):114-20.
8
Current disease-modifying therapies in multiple sclerosis.目前用于治疗多发性硬化症的疾病修正疗法。
Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138.
9
Multiple sclerosis: clinical presentation, diagnosis and treatment.多发性硬化症:临床表现、诊断与治疗
Am Fam Physician. 1996 Sep 15;54(4):1301-6, 1309-11.
10
Non-specific immunosuppressants in the treatment of multiple sclerosis.非特异性免疫抑制剂在多发性硬化症治疗中的应用
Clin Neurol Neurosurg. 2004 Jun;106(3):263-9. doi: 10.1016/j.clineuro.2004.02.012.